[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365108-105":59,"doc-detail-365108-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-triple-mode-strategy-on-jq1-loaded-nanoplatform-for-superior-antitumor-therapy-in-pancreatic-cancer","A triple-mode strategy on JQ1-loaded nanoplatform for superior antitumor therapy in pancreatic cancer","","Pancreatic cancer’s dire prognosis drives the need for innovative therapies. JQ1, a bromodomain 4 inhibitor, shows strong preclinical anti-tumor activity but is limited by rapid resistance. This work develops JQ1@MSN/FeTA-iRGD, a multifunctional nanoplatform using a triple-mode strategy that integrates apoptosis, ferroptosis, and immunogenic cell death. Tumor targeting and internalization in acidic tumor environments enable efficient JQ1 and Fe2+ release, amplified ROS and mitochondrial damage, and sustained antitumor immune responses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-triple-mode-strategy-on-jq1-loaded-nanoplatform-for-superior-antitumor-therapy-in-pancreatic-cancer/365108/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-triple-mode-strategy-on-jq1-loaded-nanoplatform-for-superior-antitumor-therapy-in-pancreatic-cancer/365108.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main therapeutic problem addressed in this study?","Question",{"text":112,"@type":113},"The study targets pancreatic cancer’s poor prognosis and the limited long-term efficacy of JQ1 due to rapid resistance development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the nanoplatform improve JQ1 delivery and tumor action?",{"text":117,"@type":113},"JQ1@MSN/FeTA-iRGD is designed to precisely target tumors and release JQ1 and Fe2+ after internalization in the acidic tumor environment.",{"name":119,"@type":110,"acceptedAnswer":120},"What triple-mode treatment mechanisms are combined to enhance antitumor effects?",{"text":121,"@type":113},"The strategy integrates apoptosis, ferroptosis, and immunogenic cell death, using amplified ROS and mitochondrial damage and immunogenic signaling from dying cancer cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365108,1790211786,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Materials Today Bio 32 (2025) 101696  \nContents lists available at ScienceDirect  \nMaterials Today Bio  \njournal [homepage:](homepage: www.journals.elsevier.com/materials-today-bio)[ www.journals.elsevier.com/materials-today-bio](homepage: www.journals.elsevier.com/materials-today-bio)  \n| A triple-mode strategy on JQ1-loaded nanoplatform for superior antitumor therapy in pancreatic cancer\u003Cbr>Zhiguo Lia,1, Jinxin Duana,1, Zhiwen Liu b,1, Weifan Lia,1, Yiyin Maia, Hao Fua,*, Guotao Yuan c,e,**, Jiawei Wang a,d,*** \u003Cbr>a Guangzhou Key Laboratory of Medical Nanomaterials, Guangdong Provincial Key Laboratory ofMalignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China\u003Cbr>b School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China c College of Chemistry and Environmental Engineering, Shenzhen University, 518060, China\u003Cbr>d Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China\u003Cbr>e Department of Otolaryngology, Longgang E.N.T. Hospital & Shenzhen Key Laboratory of E.N.T., Shenzhen, 518116, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords:\u003Cbr>Pancreatic cancer Tumor microenvironment Bromodomain Ferroptosis Immunogenic cell death |  | Pancreatic cancer’s dire prognosis urgently calls for innovative therapeutic strategies. JQ1, a bromodomain 4 inhibitor, exhibits potent anti-tumor activity in preclinical models but faces limitations due to rapid resistance development. Here, we developed a novel multifunctional nanoplatform, JQ1@MSN/FeTA-iRGD, which implemented a triple-mode strategy integrating apoptosis, ferroptosis, and immunogenic cell death for optimized treatment of pancreatic cancer. The particles could precisely target tumors in mice and achieve efficient release of JQ1 and Fe2+ through internalization in the acidic tumor environment. The nanoplatform amplified reactive oxygen species and mitochondrial damage to disrupt the redox homeostasis, thus synergistically escalating apoptosis and ferroptosis for the destruction of tumor cells, circumventing the rapid drug resistance associated with monotherapy. Meanwhile, dying cancer cells released damage-associated molecular patterns, which facilitated immunogenic cell death and triggered antitumor immune responses, guaranteeing the sustained efficacy of the treatment. Moreover, the system exhibited favorable biocompatibility, supporting its feasibility for clinical translation. Our results demonstrated that this novel strategy, combining apoptosis, ferroptosis, and immunogenic cell death, overcame the limitations of monotherapy with JQ1, providing a superior, targeted, and sustainable treatment option for pancreatic cancer. |\n\n1. Introduction  \nPancreatic cancer, with a five-year survival rate of only 5–12 %[1, 2], is the third leading cause of cancer-related deaths worldwide, posing a major challenge to international health initiatives [2–4]. It is concerning that pancreatic cancer patients often exhibit poor responses to chemotherapy [5], with a median survival of just 11 months under first-line treatments [6], highlighting the urgent need for more effective  \ntherapeutic strategies for this patient population [7]. Studies have identified bromodomain 4 (BRD4), an acetyl-lysine binding protein crucial for oncogene regulation and epigenetic modifications, as a promising cancer therapy target [8]. Inhibiting BRD4 disrupts RNA polymerase II-driven transcription, selectively targeting essential oncogenes for cancer cell survival [9–11]. JQ1, one of the initial bromodomain and extraterminal domain (BET) inhibitors identified, disrupts the association between BET proteins and acetylated lysines on histones and  \n* Corresponding author. Guangzhou Key Laboratory of Medical Nanomaterials, Guangdong Provinci","cbCailGtRlFTV2X6","https://ap.wps.com/l/cbCailGtRlFTV2X6","pdf",18135116,13,"English","# Introduction\n## Pancreatic cancer challenges and survival statistics\n## BRD4 and epigenetic targeting rationale\n## JQ1 background and resistance limitations","[{\"question\":\"What is the main therapeutic problem addressed in this study?\",\"answer\":\"The study targets pancreatic cancer’s poor prognosis and the limited long-term efficacy of JQ1 due to rapid resistance development.\"},{\"question\":\"How does the nanoplatform improve JQ1 delivery and tumor action?\",\"answer\":\"JQ1@MSN/FeTA-iRGD is designed to precisely target tumors and release JQ1 and Fe2+ after internalization in the acidic tumor environment.\"},{\"question\":\"What triple-mode treatment mechanisms are combined to enhance antitumor effects?\",\"answer\":\"The strategy integrates apoptosis, ferroptosis, and immunogenic cell death, using amplified ROS and mitochondrial damage and immunogenic signaling from dying cancer cells.\"}]","A triple-mode strategy on JQ1-loaded nanoplatform for superior antitumor therapy in pancreatic cancer | PDF",1790160048,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c60447e450b5f0a53d0c432c9cc4e67.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4add75a5faab87926200925e7a7ae720.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bbdd49621cbb239db4c86a2302f256f.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d880b119db8b1b37a439c5c6be74ee4d.webp",980,1306]